Prevalence and Risk Factors for Glucose Intolerance among Saudi Women with Gestational Diabetes

Hayfaa Wahabi

Chair of Evidence-Based Healthcare and Knowledge Translation, College of Medicine, King Saud University, P.O. Box 2925 Riyadh 11461, Saudi Arabia

Correspondence should be addressed to Hayfaa Wahabi; umlena@yahoo.com

Received 22 June 2018; Accepted 31 July 2018; Published 14 August 2018

Academic Editor: Daniela Foti

Copyright © 2018 Hayfaa Wahabi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. The objective of this study was to determine the incidence and risk factors of glucose intolerance one year after delivery in women with gestational diabetes (GDM).

Methods. All women who had GDM and completed one year since delivery at King Khalid University Hospital were contacted to participate in the study. Based on the American Diabetes Association criteria and the results of fasting blood glucose (FPG) and HbA1c, participants were classified into three groups: diabetic, impaired glucose tolerance (IGT), and normal. The incidence of diabetes and IGT was calculated. Clinical, biochemical, and sociodemographic predictors of glucose intolerance were compared between the three groups. Odds ratio (OR) for risk factors with $P$ value less than 0.05 was calculated.

Results. From a total 316 eligible women, 133 fulfilled the inclusion criteria and agreed to participate in the study. From the study participants, 58 (44%) women were normoglycemic, 60 (45%) women had IGT, and 15 (11%) women were diabetic. The odds of developing IGT or diabetes increased to nearly fourfold when women needed insulin for the control of GDM during pregnancy (OR 3.8, 95% CI 0.81–18.3, $P = 0.08$) and to nearly one-and-a-half-fold when they had positive family history of T2DM (OR 1.2, 95% CI 0.74–2.09, $P = 0.40$). Nevertheless, none of the odds ratios was statistically significant.

Conclusion. The incidence of postpartum hyperglycemia (diabetes and IGT) is very high in Saudi women with GDM. Family history of diabetes and insulin treatment of GDM may be predictors of postpartum hyperglycemia.

1. Introduction

The physiological changes of pregnancy mediate carbohydrate intolerance through pregnancy-specific hormones by increasing the peripheral resistance to insulin and production of glucose; these changes call for more production of insulin to maintain normal blood glucose levels during pregnancy [1].

Gestational diabetes (GDM) is one of the commonest metabolic disorders of pregnancy. It is defined as diabetes diagnosed during pregnancy that is clearly not pregestational in nature [2].

Long follow-up of women with history of GDM showed that they are at increased risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases later in life [3, 4].

The majority of women with GDM convert to normal glycemic status following delivery; however, they have increased risk of developing T2DM compared to women who did not have GDM [5]. The reported rate of progression to T2DM varied considerably in different studies and is dependent on the period of follow-up, the diagnostic criteria for GDM, and the ethnicity of the studied population [6]. Risk factors for progression to T2DM include family history of T2DM, need of insulin treatment, and obesity [7–10].

It has been proven that lifestyle modification and pharmacological interventions can prevent or delay progression to T2DM in women with history of GDM [11–13]. Such interventions should be considered in the management of women with GDM especially that one in four Saudi women develops GDM during pregnancy and is among the high-risk population for developing T2DM [14].
Based on the American Diabetes Association (ADA) guidelines, different tests are equally effective for screening for impaired glucose tolerance (IGT) and diabetes including 75 oral glucose tolerance test (OGTT), fasting plasma glucose (FPG), or glycosylated hemoglobin A1C (HbA1c) [15].

There is paucity of studies on the progression to T2DM among postpartum Saudi women. The objective of this study was to determine the prevalence and risk factors of glucose intolerance one year after delivery in women with GDM.

2. Methods

This is a cross-sectional study conducted at King Khalid University Hospital (KKUH) in Riyadh, Saudi Arabia. KKUH is a tertiary referral hospital with 800 beds. It has all the essential departments including 20 operating theatres, an assisted reproduction unit, and a cardiac center. The hospital provides free medical care to Saudi nationals and the staff of King Saud University. The obstetrics department provides care for 3000–4000 deliveries per year.

2.1. Definitions

(i) GDM was diagnosed based on one abnormal value of 75 g on the oral glucose tolerance test (OGTT) done between 24 and 34 gestation weeks using the following World Health Organization (WHO) cutoff values [16]:

(1) Fasting plasma glucose (FPG): 5.1–6.9 mmol/l (92–125 mg/dl),
(2) 1-Hour plasma glucose ≥ 10.0 mmol/l (180 mg/dl),
(3) 2-Hour plasma glucose: 8.5–11.0 mmol/l (153–199 mg/dl).

(ii) Diabetes and IGT were diagnosed using either fasting plasma glucose and glycosylated hemoglobin A1C (HbA1c) levels according to the following cutoff levels of the ADA [17]:

(1) Fasting plasma glucose (FPG) values:
   (a) Normal: <5.6 mmol/l (100 mg/dl)
   (b) IGT: 5.6–6.9 mmol/l (100 mg/dl to 125 mg/dl)
   (c) Diabetes: ≥7.0 mmol/l (126 mg/dl)

(2) HbA1c values:
   (a) Normal: <5.7%
   (b) IGT: 5.7%–6.4%
   (c) Diabetes: ≥6.5%

(iii) Maternal pre-pregnancy body mass index (BMI) was calculated from maternal recall of weight prior to pregnancy and height measured during the first antenatal clinic. Current BMI was calculated using the current maternal weight and height.

Participants were classified according to the following WHO BMI definitions: underweight (<18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and obese (≥30 kg/m²) [18].

2.2. Participants. Each woman who delivered one year prior to the study period (September 2017–March 2018) and had GDM during the index pregnancy was invited to participate in the study.

The inclusion criteria were as follows:

(1) Gestational age of 37–41 weeks at the time of delivery, calculated from the last menstrual period and/or early ultrasound scan
(2) Singleton pregnancy
(3) History of GDM during the index pregnancy

We excluded women with unknown glycemic status, those with pre-GDM diagnosed before or during pregnancy, women who were pregnant at the time of this study, and those who declined to participate in the study.

All women who fulfilled the inclusion criteria were contacted by phone to participate in this study. Women who agreed to participate were invited to attend a designated outpatient clinic (research clinic) fasting for at least eight hours before their appointment. The objective of the study was explained again face-to-face to each participant who subsequently signed an informed consent form. Data collected from the participants included demographic profile, obstetric history such as parity and pre-pregnancy weight, and the type of treatment of GDM in the index pregnancy (diet or insulin). Clinical data measured in each participant included current weight and height to calculate the BMI. Blood tests done for each participant were fasting blood glucose (FPG) and glycosylated hemoglobin A1c (HbA1c) levels.

Based on the results of blood tests, participants were divided into three groups: diabetic, prediabetic, and normal.

2.3. Statistical Analysis. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS version 22). The prevalence of diabetes and IGT was calculated. Clinical, biochemical, and sociodemographic characteristics of women who progressed to postpartum glucose intolerance (IGT and diabetes) were compared with women with normal glucose tolerance using univariate analysis. The odds ratio (OR) of the known risk factors and 95% confidence interval (CI) were estimated for factors with significant P value after grouping the IGT and diabetic women together in one group compared to the normoglycemic group. A P value of <0.05 was considered significant.

2.4. Ethical Approval. The study was conducted after the approval of King Saud University review board. It was conducted according to the principles expressed in the Declaration of Helsinki.
3. Results

From a total of 316 women with GDM who delivered one year prior to the study period, 133 met the inclusion criteria and agreed to participate in this study. From the participants, 58 women were normoglycemic, 60 had IGT, and 15 developed diabetes.

Table 1 shows the comparison of the distribution of the risk factors between the three groups. There were no significant differences between the three groups with respect to age and parity. However, there was increased frequency of risk factors when normoglycemic women were compared to those with IGT and those who developed diabetes (Table 1). The current mean BMI of normoglycemic women was significantly lower than that of the IGT and diabetic women (30.9 ± 6.4, 31.1 ± 5.6, 36.2 ± 4.8, resp., \( P < 0.01 \)). In addition, from the women who developed postpartum diabetes, 14 (93%) had pre-pregnancy BMI of \( \geq 30 \) kg/m\(^2\), while the corresponding proportions from the IGT group and the normoglycemic group were 24 (40%) and 31 (53%), respectively (Table 1). Significantly more women with IGT and diabetes had a family history of diabetes; in addition, they more frequently needed insulin for control of GDM during pregnancy, compared to normoglycemic women (Table 2).

Table 2 shows the odds of developing IGT or diabetes with different risk factors. The odds of developing IGT or diabetes increased to nearly fourfold when women needed insulin for the control of GDM during pregnancy and to nearly one-and-a-half-fold when they have positive family history of T2DM. On the other hand, pre-pregnancy normal BMI and diet treatment of GDM reduce the odds of developing glucose abnormalities one year postpartum. Nevertheless, none of the odds ratios for these risk factors was statistically significant (Table 2).

4. Discussion

The incidences of IGT and diabetes, in this study, were 45% and 11%, respectively. The results showed that women who developed glucose abnormalities (IGT and diabetes) were significantly more obese, during pregnancy and in the postpartum period. Furthermore, a significantly higher proportion from this group had a family history of T2DM. On the other hand, pre-pregnancy normal BMI and diet treatment of GDM reduce the odds of developing glucose abnormalities one year postpartum. Nevertheless, none of the odds ratios for these risk factors was statistically significant (Table 2).

4.1. Strength and Limitations of the Study. This study quantified the problem of glucose intolerance following GDM in a Saudi population and provides valuable information for policymakers and researchers about the risk factors for the progression to T2DM in Saudi women. One of the limitations of this study is the relatively small number of participants compared to the total number of women who had GDM during the study period. This is due to the poor postpartum response to recall for follow-up, a problem faced by other researchers in the Middle East [25].

4.2. Implication to Practice

(i) Establishing a national program for screening women with a history of GDM for diabetes and prediabetes should be a health-service priority in a strategy for controlling the epidemic of diabetes in the country. Such programs were proven to be cost-effective considering the saving in the cost of premature death and treatment of complications of diabetes [26].

(ii) Implementation of evidence-based national guidelines for the treatment of GDM that includes lifestyle
Modification is an essential step in the control of postpartum progression to T2DM.

4.3. Implication to Research. Research should be directed towards effective interventions to reduce the burden of obesity in Saudi pregnant and postpartum women.

4.4. Conclusion. The incidence of postpartum IGT and diabetes is very high in Saudi women with GDM. Treatment of GDM with insulin and a family history of T2DM may be predictors of the progression to IGT and T2DM.

Data Availability
The data used to support the findings of this study are included within the article.

Disclosure
The funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest
The author declares that she has no conflict of interest for the publication of this research.

Acknowledgments
This study is funded by the Deanship of Scientific Research at King Saud University. Thanks are due to all women who...
References

[1] E. A. Ryan and L. Enns, “Role of gestational hormones in the induction of insulin resistance,” The Journal of Clinical Endocrinology and Metabolism, vol. 67, no. 2, pp. 341–347, 1988.

[2] American Diabetes Association, “Management of diabetes in pregnancy,” Diabetes Care, vol. 39, Supplement 1, pp. S94–S98, 2016.

[3] L. Bellamy, J. P. Casas, A. D. Hingorani, and D. Williams, “Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis,” The Lancet, vol. 373, no. 9677, pp. 1773–1779, 2009.

[4] E. P. Gunderson, V. Chiang, M. J. Pletcher et al., “History of gestational diabetes mellitus and future risk of atherosclerosis in mid-life: the coronary artery risk development in young adults study,” Journal of the American Heart Association, vol. 3, no. 2, article e000490, 2014.

[5] A. Tovar, L. Chasan-Taber, E. Eggleston, and E. Oken, “Postpartum screening for diabetes among women with a history of gestational diabetes mellitus,” Preventing Chronic Disease, vol. 8, no. 6, article A124, 2011.

[6] L. Leuridan, J. Wens, R. Devlieger, J. Verhaeghe, C. Mathieu, and K. Benhalima, “Glucose intolerance in early postpartum women with gestational diabetes: who is at increased risk?,” Primary Care Diabetes, vol. 9, no. 4, pp. 244–252, 2015.

[7] K. Baptiste-Roberts, B. B. Barone, T. L. Gary et al., “Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review,” The American Journal of Medicine, vol. 122, no. 3, pp. 207–214.e4, 2009.

[8] C. E. Eades, M. Styles, G. P. Leese, H. Cheyne, and J. M. Evans, “Progression from gestational diabetes to type 2 diabetes in one region of Scotland: an observational follow-up study,” BMC Pregnancy and Childbirth, vol. 15, no. 1, p. 11, 2015.

[9] D. S. Feig, B. Zinman, X. Wang, and J. E. Hux, “Risk of development of diabetes mellitus after diagnosis of gestational diabetes,” CMAJ, vol. 179, no. 3, pp. 229–234, 2008.

[10] G. Rayanagoudar, A. A. Hashi, J. Zamora, K. S. Khan, G. A. Hitman, and S. Thangaratinam, “Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women,” Diabetologia, vol. 59, no. 7, pp. 1403–1411, 2016.

[11] M. Hod, E. Hadar, and L. Cabero-Roura, “Prevention of type 2 diabetes among women with prior gestational diabetes mellitus,” International Journal of Gynaecology and Obstetrics, vol. 131, pp. S16–S18, 2015.

[12] S. L. O’Reilly, J. A. Dunbar, V. Versace et al., “Mothers after gestational diabetes in Australia (MAGDA): a randomised controlled trial of a postnatal diabetes prevention program,” PLoS Medicine, vol. 13, no. 7, article e1002092, 2016.

[13] A. S. Peacock, F. Bogossian, H. D. McIntyre, and S. Wilkinson, “A review of interventions to prevent type 2 diabetes after gestational diabetes,” Women and Birth, vol. 27, no. 4, pp. e7–e15, 2014.

[14] H. Wahabi, A. Fayed, S. Esmaeil, H. Mamdouh, and R. Kotb, “Prevalence and complications of pregestational and gestational diabetes in Saudi women: analysis from Riyadh mother and baby cohort study (RAHMA),” BioMed Research International, vol. 2017, Article ID 6878263, 9 pages, 2017.

[15] American Diabetes Association, “Glycemic targets: standards of medical care in diabetes—2018,” Diabetes Care, vol. 41, Supplement 1, pp. S55–S64, 2018.

[16] N. W. Cheung and D. Helmink, “Gestational diabetes: the significance of persistent fasting hyperglycemia for the subsequent development of diabetes mellitus,” Journal of Diabetes and its Complications, vol. 20, no. 1, pp. 21–25, 2006.

[17] C. Capula, E. Chiefiari, A. Vero, D. P. Foti, A. Brunetti, and R. Vero, “Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 223–230, 2014.

[18] K. Lohner, A. Knopff, A. Baumgarten et al., “Predictors of postpartum diabetes in women with gestational diabetes mellitus,” Diabetes, vol. 55, no. 3, pp. 792–797, 2006.

[19] K. Al-Rubeaan, H. A. Al-Manaa, T. A. Khoja et al., “Epidemiology of abnormal glucose metabolism in a country facing Its epidemic: SAUDI-DM study,” Journal of Diabetes, vol. 7, no. 5, pp. 622–632, 2015.

[20] A. J. Al-Quwaïdhi, M. S. Pearce, E. Sobngwi, J. A. Critchley, and M. O’Flaherty, “Comparison of type 2 diabetes prevalence estimates in Saudi Arabia from a validated Markov model against the international diabetes federation and other modelling studies,” Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 496–503, 2014.

[21] S. Nouhjaj, H. Shabbazian, N. Shabbazian, A. Jahanshahi, S. Jahanfar, and B. Cheraghian, “Incidence and contributing factors of persistent hyperglycemia at 6-12 weeks postpartum in Iranian women with gestational diabetes: results from LAGA cohort study,” Journal of Diabetes Research, vol. 2017, 9 pages, 2017.

[22] H. Wahabi, A. Fayed, S. Esmaeil et al., “Riyadh mother and baby multicenter cohort study: the cohort profile,” PLoS One, vol. 11, no. 3, article e0150297, 2016.

[23] J. Brown, N. A. Alwan, J. West et al., “Lifestyle interventions for the treatment of women with gestational diabetes,” Cochrane Database of Systematic Reviews, vol. 5, article CD011970, 2017.

[24] V. R. Aroda, C. A. Christophi, S. L. Edelstein et al., “The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the diabetes prevention program outcomes study 10-year follow-up,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 4, pp. 1646–1653, 2015.

[25] H. Shabbazian, S. Nouhjaj, S. Jahanfar, and M. Nasiri, “Recall for postpartum follow-up of women with gestational diabetes mellitus: climbing a mountain,” Journal of Diabetes and Metabolic Disorders, vol. 15, no. 1, p. 20, 2015.

[26] E. Marseille, N. Lohse, A. Jiwani et al., “The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 26, no. 8, pp. 802–810, 2013.